PsychedelicNewsBreaks

TuesdayJan 12, 2021 1:45 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Leverages Key Experience, Prepares Entry into Psychedelic Mushroom Market

Pure Extracts (CSE: PULL), a plant-based extraction company, is focused on cannabis, hemp, and functional mushroom sectors, the last of which is projected to rise to a value of $34.4 billion by the end of 2024. Seeking to capitalize on the growing interest within the sector, Pure Extracts has expanded its business model to include mushroom formulations using extraction processes proven compatible with the company’s existing infrastructure. Working alongside its scientific advisor—Dr. Alexander MacGregor, founder of the Toronto Institute of Pharmaceutical Technology—Pure Extracts intends to develop high bio-available products and novel delivery methodologies, which will include tinctures, pills, capsules and…

Continue Reading

MondayJan 11, 2021 11:47 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces New CFO, General Counsel

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) chairman and CEO Roger McIntyre today announced the company's appointment of Stephen R. Brooks as its new chief financial officer and Peter Rizakos as the firm's new general counsel. According to the update, these appointments complete the company's new top management team put into place by Dr. McIntyre and the Champignon Board of Directors.  "These new management additions ready us for the future where the Company's clinical products and services will help meet the enormous public need that is creating significant public demand for improved, ketamine-based treatments that are capable of rapid response…

Continue Reading

MondayJan 11, 2021 11:19 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Strategic Partnership with Kernel

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, is excited to announce that it has entered into an agreement with neurotech pioneer HI, LLC dba Kernel (“Kernel”) to leverage its innovative technology, Kernel Flow (“Flow”), for its upcoming sponsored clinical work. “Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction. Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug development programs is potentially…

Continue Reading

FridayJan 08, 2021 11:31 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Article Outlining Future Potential in Novel Agents for Bipolar Disorders

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article, “Bipolar Disorders” is published in The Lancet – one of the world's best-known and most reputable scientific journals in medicine. According to the update, the article contributes to The Lancet 's collection of peer-reviewed seminars and provides a "state-of-the-art overview of bipolar disorders, covering epidemiology, parthenogenesis, diagnosis, treatment, and prevention, while highlighting relevant clinical controversies." "The availability of so-called rapid-onset treatments (e.g., ketamine) and treatments that could mitigate suicidality is crucial to clinical settings,"…

Continue Reading

ThursdayJan 07, 2021 11:33 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces Listing on OTC Markets, Now Trading Under PRXTF Symbol

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, recently received approval from OTC Markets and is  now trading under the ticker symbol PRXTF (“PRXTF”). OTC Markets is recognized for offering Canadian companies the benefits of being publicly traded in the United States but with lower cost and complexity than a U.S. exchange listing. To be eligible to list on the OTC Exchange, Canadian companies must undergo an annual verification and management certification process and be up-to-date with their SEDAR reporting. Moving forward, Pure Extracts will continue to trade on…

Continue Reading

WednesdayJan 06, 2021 2:08 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Releases Report on Patent Filings, Therapeutics Program Development

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, has provided an update on its patent filings. The company has eight filings, all tied to Cybin’s novel therapeutics, delivery mechanisms and treatment regiments. The patent updates noted that Cybin has patent applications for the following: a provisional patent application for an oral film delivery mechanism covering all psychedelic molecules delivered through oral films; a delivery technology covering various chemically synthesized psychedelic molecules; multiple patent applications for deuterated psychedelic molecules and analogues; and a patent application for platforms that create supportive treatment regimens. The company also announced that…

Continue Reading

WednesdayDec 30, 2020 10:33 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) Commences Study to Further Knowledge in Psilocybin, Associated Delivery Mechanisms

Pure Extracts Technologies (CSE: PULL) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushrooms sector, today announced that it is commencing a study on the formulation and manufacturing of psilocybin-based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. According to the update, the study with be conducted at the Toronto Institute of Pharmaceutical Technology (“TIPT”) by Dr. Alexander MacGregor, a key scientific advisor to Pure Extracts. The study will focus on formulating, manufacturing and clinical bioavailability testing of rapid onset psilocybin dosage forms…

Continue Reading

WednesdayDec 30, 2020 10:25 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Announces Q1 Results for Clarmin Explorations

Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, on Tuesday announced the unaudited financial results of Clarmin Explorations Inc. (now Cybin Inc.) for the three month period ended Oct. 31, 2020. According to the update, a copy of the consolidated financial statements prepared in accordance with International Financial Reporting Standards, as well as the corresponding management’s discussion and analysis for the three months ended Oct. 31, 2020, can be found under Cybin’s profile at www.SEDAR.com. To view the full press release, visit https://ibn.fm/br5Uw About Cybin Inc. Cybin is a life sciences company advancing psychedelic pharmaceutical treatments…

Continue Reading

MondayDec 28, 2020 2:22 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) on Track to Leverage Psychedelics to Target Depression

Cybin (NEO: CYBN), a mushroom life science company, is set to leverage opportunity amid growing research that demonstrates the significant role psilocybin could play in alleviating symptoms of major depression. According to a recent study conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry,” only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in symptoms in adults with major depression (https://ibn.fm/ZpmzM). “The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” stated Alan Davis, PhD., adjunct assistant professor of psychiatry and…

Continue Reading

WednesdayDec 23, 2020 2:08 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Looks to Play ‘Pivotal Role’ in Supply Chain

Pure Extracts (CSE: PULL), a plant-based extraction company focused on cannabis, hemp and functional mushroom sectors, recently began trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL.” Pure Extracts leverages proprietary CO2 extraction methodology to obtain full-spectrum oil (“FSO”) from cannabis and hemp biomass. “We are pleased to have listed on the Canadian Securities Exchange as a significant first step towards Pure Extracts’ continual expansion within the emerging extraction space,” said Pure Extracts’ CEO Ben Nikolaevsky in a recent update. “There currently is a tremendous opportunity for growth in consumer natural health products, for which we plan on…

Continue Reading